London, 1 November 2021 – Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announces that it has entered into an exclusive licensing agreement with Almirall S.A., a global biopharmaceutical company, to commercialise FinjuveTM in certain Middle East and North Africa (MENA) markets.
1 November 2021
Product, Press Release
FinjuveTM is a finasteride spray that is approved in Italy, Germany, Luxembourg and Portugal for the treatment of androgenetic alopecia.
Under the terms of the licensing agreement, Hikma will be responsible for the registration and commercialisation of the product in certain MENA markets and Almirall will be responsible for product supply.
Mazen Darwazah, Hikma’s Executive Vice Chairman and President of MENA said, “We are excited to partner with Almirall and bring FinjuveTM to our androgenetic alopecia patients in MENA, broadening the range of treatment choices available. This collaboration augments our growth in dermatology, a key therapeutic area for Hikma, and adds a differentiated product to our portfolio. We look forward to working with Almirall.”
About FinjuveTM (topical finasteride)
Finjuve is the new formulation of Finasteride indicated for the treatment of androgenetic alopecia in adult men. Finjuve has been proved to have an equivalent efficacy to oral finasteride 1mg tablets with good safety profile, a localized therapeutic effect & a minimized absorption and exposure throughout the body. Finjuve showed clinical and statistically significant differences compared to placebo with a 3-fold effect in hair count increase from baseline at 24 weeks after administration. Finjuve was developed to penetrate into the scalp hair follicles with a water-soluble semi-synthetic polymer with high skin affinity. Also, Finjuve is efficiently applied to the scalp through a cone that prevents from spreading outside and improves overall safety.